Skip to content
Navigate to homepage - Cerba Research
Resource Library

Fact Sheet – Advancing Your Solid Tumor Trials With Our Cutting-Edge Assay Portfolio

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone, with 55%+ being solid tumors such as lung, breast, and colorectal cancers. The central and specialty laboratories’ expertise includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), AI in image analysis, and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Unveiling the Oncology Journey: Highlighting Cutting-Edge Capabilities

Cerba Research has conducted nearly 200 oncology trials within the last 5 years alone. Its experience extends to both solid and liquid tumors and includes specialized assays such as next-generation sequencing (NGS), flow cytometry (FCM), immunohistochemistry (IHC), and NanoString®. Check our latest fact sheet to learn more about our highlights and capabilities.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Virology Center of Excellence: Illuminating Insights Into Infectious Diseases

Experience the unparalleled activity of Cerba Research’s Infectious Diseases (ID) therapy sector, boasting a remarkable track record of over 600 executed trials in just the last 5 years.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Fact Sheet – Unlocking The Potential Of Rare Disease Drug Development

Discover the extraordinary world of rare diseases, where uniqueness defines the landscape. While these conditions may lack a singular definition, they encompass a myriad of fascinating conditions waiting to be understood and treated.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help advance your research

Contact Us
Resource Library

Case Study – Evidence For The Utility Of AI In Ki-67 Quantification In Solid Tumors

Although it is an important biomarker in oncology (mostly in breast and prostate), Ki-67 immunohistochemistry (IHC) analysis has yet to be standardized. Working groups have provided guidelines for Ki-67 scoring in different cancer types to limit pathologist’s variability.

Digital analysis solutions to assist scoring with image analysis or artificial intelligence (AI) have recently emerged in the evaluation of Ki-67 as rapid and robust solutions. In this context, we compared the results of Ki-67 scoring performed with Aiforia Platform ® (AI platform) and Halo ® (image analysis supervised software) against three independent pathologists on various solid tumors.

Discover more about this in the case study.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and see how we can transform research and advance health together

Contact Us
Resource Library

Poster – Validation Of NanoString® Technologies For Solid Tumor Clinical Studies

Cerba Research Montpellier (CRM), a leader in histopathology and part of the Cerba Research group, is revolutionizing solid tumor clinical trials with our cutting-edge NanoString® platforms. Specializing in multiplex immunofluorescence for FFPE tissues, our lab now offers unparalleled transcriptomic and proteomic analysis capabilities.

Transforming Solid Tumor Clinical Trials with NanoString® Technology

Our recent acquisition of NanoString® technology enhances precision in solid tumor research. We have validated RNA analysis protocols for both bulk analysis using nCounter and spatial analysis with the GeoMx DSP platform’s whole transcriptome atlas (WTA). This advancement opens new doors in cancer research, extending potentially to other therapeutic areas.

Delve deeper into our innovative approach and its impact on solid tumor clinical trials by exploring our poster from SITC 2023. It showcases our advanced techniques and their applications in transformative cancer research.

NanoString’s nCounter Pro analysis system

Reach out to our experts and discover how we can transform research and advance health together

Contact Us
Resource Library

Brochure – Meeting The Challenges You Face With PBMC- All Your Global PBMC Needs Delivered

There are important questions you need to ask yourself and any potential laboratory partner before you start a study including PBMC assays as part of your protocol. When looking at the laboratory partner for your PBMC processing, approaching potential partners with the end in mind is important to ensure that you will be able to generate the data you need in the future.

Cerba US Expansion Tour VF.00_04_27_19.Still010

Reach out to our experts and discover how we can help you advance your clinical trial

Contact Us
Resource Library

Poster – Implementation Of Cytek® Aurora Instruments In Clinical Trials: A Multi-step Process Including Performance Qualification And Standardization


Experience the power of Cytek® Aurora instruments in global clinical trials. Our multi-step process, led by a team from Cerba Research and Cytek Biosciences, focuses on performance qualification and standardization to unlock the full potential of high-parameter spectral flow cytometry. Explore our journey through performance qualification, assessing optical alignment, system resolution, stability of lasers and detectors, and analytical validation.

Harmonizing Excellence: Unleashing High-Parameter Spectral Flow Cytometry in Global Clinical Trials with Cytek® Aurora Instruments

Explore the intersection of high-parameter spectral flow cytometry and global clinical trials through our meticulous process at Cerba Research, Ghent, Belgium, and Cytek Biosciences, California, USA. We delve into instrument standardization’s critical role for transparent results across labs and introduce innovative methods for implementing and standardizing Cytek® Aurora Instruments.

Witness our multi-step process, evaluating optical alignment, system resolution, laser and detector stability, and analytical validation. Our in-house workflow ensures precision, with deviations well within acceptance criteria. Discover the effectiveness of SpectraComp® beads for spectral unmixing, reducing errors and optimizing workflow.

Join us as we demonstrate instrument comparability and consistent performance, propelling forward the standardization of Cytek® Aurora Instruments for reliable insights in global clinical trials.

Reach out to our experts and discover how we can transform research and advance health together

Contact Us
Resource Library

Poster – Validation Of A Flow Cytometry Assay On Cytek® Aurora To Monitor Immune Cells In Peripheral Whole Blood For Clinical Trials

Discover the cutting-edge of immune monitoring in global clinical trials. Our 14-color assay, validated meticulously for hematological malignancies, utilizes spectral flow cytometry for a comprehensive understanding of T cells, B cells, NK cells, monocytes, and subsets. Elevate standards in drug development and improve patient outcomes worldwide.

Advancing Immune Monitoring: Validation of a 14-color Assay for Hematological Malignancies and Cell & Gene Therapy Trials

Explore our validated 14-color assay, a breakthrough in immune monitoring for hematological malignancies and cell & gene therapy trials. Using spectral flow cytometry, our method offers in-depth characterization of T cells, B cells, NK cells, and monocytes, crucial for global clinical trials.

The assay’s precision, demonstrated through repeatability, reproducibility, and inter-operator variability, ensures reliable data interpretation. Notably, viability dye titration and sample stability evaluations enhance the assay’s robustness.

Our commitment to advancing drug development is exemplified through this cutting-edge flow cytometry assay, providing a comprehensive and reliable tool for monitoring immune cells in peripheral whole blood across diverse clinical settings.

Reach out to our experts and discover how we can transform research and advance health together

Contact Us
Resource Library

Poster – Comparison Of BD FACSLyric™ Instrument Performance In A Global Setting

Flow cytometry, recognized for its unparalleled capacity in characterizing cellular populations, necessitates the implementation of standardized instruments both within and across various laboratories, particularly for conducting global clinical trials. A pivotal component in achieving this standardization is the Cytometer Setup & QC software featured in the BD FACSLyric™ instrument. This software is engineered to correct daily fluctuations not only within a single instrument but also across multiple instruments, leveraging the Bright Bead Median Target Values (BBMTV).

Enhancing Standardization in Flow Cytometry for Global Clinical Trials

In our efforts to validate the efficacy of this software module in standardizing flow cytometry assays, we undertook a comprehensive evaluation. This involved assessing the Median Fluorescence Intensity (MFI) both between different instruments and within the same instrument over time. For this purpose, we utilized two distinct types of calibration particles: BD® Cytometer Setup and Tracking (CS&T) beads, provided by BD Biosciences, and SPHERO™ Ultra Rainbow calibration particles, from Spherotech.

The focus on maintaining consistent performance in flow cytometry, through the use of advanced software and calibration methods, is crucial in ensuring the reliability and accuracy of results obtained from these sophisticated instruments. This is especially significant in the context of global clinical trials, where standardization across different settings is key to obtaining universally applicable and credible data.

Reach out to our experts and discover how we can transform research and advance health together

Contact Us